 HAMPTON, N.J., June 01, 2021 GLOBE NEWSWIRE -- Celldex Therapeutics, Inc. NASDAQ:CLDX today announced that an abstract describing results from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria ColdU and symptomatic dermographism SD, the two most common forms of chronic inducible urticaria CIndU, has been accepted as a late-breaking electronic Poster Discussion Session ePDS at the European Academy of Allergy and Clinical Immunology EAACI Annual Congress 2021, being held July 10-12, 2021. The ePDS is chaired and will consist of a pre-recorded presentation followed by questions from session chairs during a dedicated timeslot. 